[HTML][HTML] Phase 1 trials of rVSV Ebola vaccine in Africa and Europe
Background The replication-competent recombinant vesicular stomatitis virus (rVSV)–based
vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid safety …
vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid safety …
The role of penicillin in benign skin rashes in childhood: a prospective study based on drug rechallenge
JC Caubet, L Kaiser, B Lemaître, B Fellay… - Journal of Allergy and …, 2011 - Elsevier
BACKGROUND: Delayed-onset urticarial or maculopapular rashes are frequently observed
in children treated with β-lactams. Many are labeled “allergic” without reliable testing. …
in children treated with β-lactams. Many are labeled “allergic” without reliable testing. …
Maternal immunization earlier in pregnancy maximizes antibody transfer and expected infant seropositivity against pertussis
…, G Blanchard-Rohner, B Lemaître… - Clinical Infectious …, 2016 - academic.oup.com
Background. Maternal immunization against pertussis is currently recommended after the
26th gestational week (GW). Data on the optimal timing of maternal immunization are …
26th gestational week (GW). Data on the optimal timing of maternal immunization are …
[HTML][HTML] The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial
Background Safe and effective vaccines against Ebola could prevent or control outbreaks.
The safe use of replication-competent vaccines requires a careful dose-selection process. We …
The safe use of replication-competent vaccines requires a careful dose-selection process. We …
Pertussis antibody transfer to preterm neonates after second-versus third-trimester maternal immunization
…, G Blanchard-Rohner, B Lemaître… - Clinical Infectious …, 2017 - academic.oup.com
Preterm infants are most vulnerable to pertussis. Whether they might benefit from maternal
immunization is unknown. Extending our previous results in term neonates, this observational …
immunization is unknown. Extending our previous results in term neonates, this observational …
[HTML][HTML] Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort …
…, J Brosnahan, TP Monath, B Lemaître… - The Lancet Infectious …, 2018 - thelancet.com
Background The recombinant vesicular stomatitis virus (rVSV) vaccine expressing the Zaire
Ebola virus (ZEBOV) glycoprotein is efficacious in the weeks following single-dose injection, …
Ebola virus (ZEBOV) glycoprotein is efficacious in the weeks following single-dose injection, …
[BOOK][B] Preserving and exhibiting media art
J Noordegraaf, CG Saba, B Le Maître, V Hediger - 2013 - muse.jhu.edu
FILM framing film is a book series dedicated to theoretical and analytical studies in restoration,
collection, archival, and exhibition practices, in line with the existing archive of EYE Film …
collection, archival, and exhibition practices, in line with the existing archive of EYE Film …
Influence of timing of maternal pertussis immunization on the avidity of transferred antibodies in term and preterm neonates
…, V Othenin-Girard, A Chilin, B Lemaître… - Clinical Infectious …, 2023 - academic.oup.com
The timing of maternal pertussis vaccination influences the titers of cord-blood anti-pertussis
antibodies. Whether it affects their avidity is unknown. We demonstrate in 298 term and 72 …
antibodies. Whether it affects their avidity is unknown. We demonstrate in 298 term and 72 …
[HTML][HTML] Usefulness of a systematic approach at listing for vaccine prevention in solid organ transplant candidates
G Blanchard-Rohner, N Enriquez, B Lemaître… - American Journal of …, 2019 - Elsevier
Solid organ transplant (SOT) candidates may not be immune against potentially vaccine-preventable
diseases because of insufficient immunizations and/or limited vaccine responses. …
diseases because of insufficient immunizations and/or limited vaccine responses. …
[HTML][HTML] Safety and immunogenicity of the epicutaneous reactivation of pertussis toxin immunity in healthy adults: a phase I, randomized, double-blind, placebo …
…, M Rohr, A Matthey, G Gutknecht, B Lemaître… - Clinical Microbiology …, 2021 - Elsevier
Objectives Protection induced by acellular vaccines can be short, requiring novel immunization
strategies. Objectives of this study were to evaluate safety and capacity of a recombinant …
strategies. Objectives of this study were to evaluate safety and capacity of a recombinant …